Midostaurina anticorpo monoclonale per il trattamento della Leucemia Mieloide Acuta

Midostaurin, a monoclonal antibody for the treatment of acute myeloid leukemia in patients expressing the FMS-like tyrosine kinase 3 mutation, is now available in Italy. In the battle against blood cancers, new hope has emerged with the introduction of "Midostaurin," a revolutionary treatment for patients with acute myeloid leukemia (AML). This monoclonal antibody has been shown to have a significant impact on AML patients expressing the FLT3 gene mutation, a characteristic present in approximately one-third of all AML cases. Midostaurin's key differentiator is its ability to target leukemia cells, providing effective and less invasive treatment. Acute myeloid leukemia is a devastating disease that primarily affects older adults, with an average age of diagnosis around 60-65. This form of leukemia causes uncontrolled proliferation of bone marrow cells, hindering the production of red blood cells, white blood cells, and platelets, leading to anemia, the risk of infections, and severe bleeding. Furthermore, genetic mutations within bone marrow cells contribute to the production of abnormal proteins, further compromising cell function. However, the outlook for AML patients is improving thanks to recent advances in research. In addition to traditional chemotherapy and bone marrow transplantation, targeted drugs such as Midostaurin are now available, which has been shown to effectively inhibit the FLT3 mutation responsible for AML in a third of cases. This drug, administered orally, is well tolerated by patients and offers a survival expectancy of 25–70 months, reducing the risk of death by 23%. Importantly, although AML is typically a disease of the elderly, researchers are seeking to tailor treatments to take into account the comorbidities and specific characteristics of elderly patients. This includes the use of targeted drugs like midostaurin, which can be administered even in frail patients, opening up new therapeutic opportunities. AML still represents a significant challenge, but research and pharmaceutical innovation are bringing new hope for patients with this disease. Midostaurin is just one of the promising drugs in development, and commitment to research continues to be crucial to improving the prognosis and quality of life of AML patients. Interviews with Professors Giuseppe Rossi, Director of Hematology and Clinical Oncology, Spedali Civili di Brescia; Felicetto Ferrara, of the Hematology Division at Cardarelli Hospital in Naples; and Francesco Lo Coco, Professor of Hematology at Tor Vergata University in Rome. #midostaurina #AML #leukemia English: The video is about a treatment for acute myeloid leukemia (AML) called Midostaurin. It is available in Italy and works specifically on leukemia cells that express the FLT3 gene mutation, which is present in about a third of all patients with AML. Midostaurin is an oral therapy and has been shown to lead to a 25-70 month survival rate and a 23% reduction in the risk of death. The speaker defines AML as a blood cancer that arises from cells in the bone marrow, causing abnormal cell growth and leading to a shortage of normal blood cells, increasing the risk of anemia, infections, and bleeding. The speaker explains that the cancer is caused by genetic mutations in the bone marrow cells and that it typically affects people over the age of 60. Midostaurin is a targeted therapy that selectively targets the abnormal cells with the FLT3 gene mutation, rather than normal cells, and is better tolerated than chemotherapy and bone marrow transplant. The speaker says that the results are already promising and that the research is ongoing. [00:00] - Introduction to Midostaurin for Acute Myeloid Leukemia [00:34] - Description of Acute Myeloid Leukemia and its consequences [01:10] - Genetic mutations in Acute Myeloid Leukemia [02:17] - Traditional treatments and the new therapy with Midostaurin [03:26] - Considerations regarding patient age and comorbidities [04:37] - Acute Myeloid Leukemia in elderly patients and innovative drugs [06:26] - Clinical trials and access to innovative drugs [09:03] - Progress in research and Italy's role in the fight against Acute Myeloid Leukemia